Campagne G. auteur aut IRD Garba A. auteur aut IRD Schuchat A. auteur aut IRD Boulanger Denis auteur aut IRD Plikaytis B.D. auteur aut IRD Ousseini M. auteur aut IRD Chippaux Jean-Philippe auteur aut IRD text journalArticle eng text/pdf reformatted digital access Despite near elimination of Haemophilus influenzae b (Hib) meningitis from several industrialized countries following introduction of conjugate Hib vaccines into infant immunization schedules, Hib remains a major cause of meningitis and pneumonia in resource-poor countries. In Niger, Hib causes nearly 200 cases of meningitis per 100,000 children < one year of age, and > 40% of cases are fatal. We evaluated the immunogenicity of Hib polysaccharide-tetanus toxoid conjugate vaccine (PRP-T) administered in the same syringe as diphtheria-tetanus-pertussis (DTP) vaccine among infants in Niger. Infants were randomized into group 1 (PRP-T at six, 10, and 14 weeks), group 2 (PRP-T at 10 and 14 weeks), or a control group (meningococcal A/C polysaccharide vaccine). By 14 weeks of age, all subjects in groups 1 and 2 had 0.15 or more microg/ml of anti-PRP antibody, and 82% versus 76% had 1.0 or more microg/ml of antibody (P = not significant). By nine months of age the proportion of infants with 0.15 or more and 1.0 or more microg/ml was group 1 = 97% and 76% ; group 2 = 93% and 67% ; controls = 10% and 2.6%. Four weeks after the first, second, and third doses of PRP-T, infants in group 1 showed geometric mean titers (GMTs) of 0.19, 3.97, and 6.09 microg/ml while infants in group 2 had GMTs of 2.40 and 4.41 microg/ml four weeks after the delayed first and second doses. Both PRP-T groups had significantly higher GMTs at 18 weeks and nine months of age than infants in the control group. The Hib PRP-T vaccine was immunogenic in infants in Niger. The strong response after PRP-T was initiated one month after the first DTP vaccination may reflect carrier priming. Two dose schedules of PRP-T should be given serious consideration, particularly if their reduced cost permits vaccine introduction that would be otherwise unaffordable. (Résumé d'auteur) specialized SANTE PUBLIQUE VACCINATION NOURRISSON ANTICORPS DOSAGE EFFICACITE ANALYSE STATISTIQUE MENINGITE NIGER NIAMEY 052MALTRA05 59 5 837-842 1998 0002-9637 https://www.documentation.ird.fr/hor/fdi:010016144 0002-9637 [F B010016144] https://www.documentation.ird.fr/hor/fdi:010016144 https://horizon.documentation.ird.fr/exl-doc/pleins_textes/pleins_textes_7/b_fdi_53-54/010016144.pdf IRD - Base Horizon / Pleins textes 1998-12-07 2018-06-19 fdi:010016144 fre